A
Ajay Ashok Bhojwani
Researcher at University of Liverpool
Publications - 3
Citations - 4
Ajay Ashok Bhojwani is an academic researcher from University of Liverpool. The author has contributed to research in topics: Trastuzumab & Pertuzumab. The author has an hindex of 1, co-authored 1 publications receiving 1 citations.
Papers
More filters
Journal ArticleDOI
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
Benjamin Hall,Ajay Ashok Bhojwani,Helen Wong,Andrea Law,Helen Flint,Eliyaz Ahmed,Helen Innes,Joanne Cliff,Zafar Malik,J. O'hagan,Allison Hall,Raj Sripadam,Shaun Tolan,Zulfiqar Ali,Clare Hart,Douglas Errington,Farida Alam,Rosa Giuliani,Shaveta Mehta,S. Khanduri,Nicky Thorp,Richard J. Jackson,Silvia Cicconi,Carlo Palmieri +23 more
TL;DR: In this article , the real-world efficacy and toxicity of neoadjuvant trastuzumab and pertuzumaab combined with chemotherapy for HER2-positive breast cancers (BC) have been investigated.
Journal ArticleDOI
Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer.
Benjamin Hall,Ajay Ashok Bhojwani,Helen Innes,Eliyaz Ahmed,Joanne Cliff,Zaf Malik,Julie O’Hagan,Shaun Tolan,Allison Hall,Khizar Hayat,Douglas Errington,Farida Alam,Nicky Thorp,Helen Flint,Andrea Law,Helen Wong,S O'Reilly,Richard J. Jackson,Silvia Cicconi,Carlo Palmieri +19 more
TL;DR: Neoadjuvant HER2 blockade with trastuzumab and pertuzumAB results in pathological complete response (pCR) rates of 39% to 62% and diarrhoea is reported in up to 73% of patients.
Journal ArticleDOI
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program.
Carlo Palmieri,Catherine Harper-Wynne,Duncan Wheatley,Gianfilippo Bertelli,Iain R. Macpherson,Mark R. Nathan,Ajay Ashok Bhojwani,Mark Verrill,Joelsson-Alm Eva,Ruhe Chowdhury +9 more